中国科学院机构知识库网格
Chinese Academy of Sciences Institutional Repositories Grid
首页 机构 成果 学者
  
  1. CAS IR Grid
  2. 上海药物研究所
  3. 中国科学院上海药物研究所
  4. 国家级研究中心
  5. 原创新药研究全国重点实验室
Rebalancing the inflammatory trajectory from inflammatory bowel disease to colitis-associated colorectal cancer via artemisinin-based multitarget therapy

文献类型：期刊论文

作者He, Shi-jun2; Tang, Mei-lin1; Chen, Li5,6; Zuo, Jian-ping5,6; Xu, Han-chen3,4; Lin, Ze-min3,4
刊名ACTA PHARMACOLOGICA SINICA
出版日期2026-02-05
页码14
关键词inflammatory bowel disease colorectal cancer artemisinins anti-inflammatory therapeutics immune modulation carcinogenesis
ISSN号1671-4083
DOI10.1038/s41401-025-01747-9
英文摘要Inflammatory bowel disease (IBD) comprises Crohn's disease and ulcerative colitis, and that is a major risk factor for colitis-associated colorectal cancer (CAC), a distinct and aggressive malignancy driven by chronic intestinal inflammation. Artemisinins, a group of sesquiterpene lactones derived from Artemisia annua, have emerged as promising therapeutic candidates for IBD due to their potent anti-inflammatory and anticancer properties. In this review, we summarize the current evidence that artemisinins exert diverse pharmacological actions including modulation of immune responses, reduction of oxidative stress, preservation of epithelial barrier function, and suppression of oncogenic signaling relevant to IBD and CAC. We also introduce the recent progress in formulation strategies designed to enhance the bioavailability, tissue specificity, and therapeutic efficacy of artemisinin-based agents. By bridging traditional medical philosophy with modern pharmacological insights, artemisinins represent a versatile platform for preventing and treating inflammation-driven colorectal cancer. This review offers a comprehensive overview of their translational potential in addressing the IBD-CAC continuum.
WOS关键词ULCERATIVE-COLITIS ; DELIVERY-SYSTEM ; CROHNS-DISEASE ; ARTESUNATE ; DIHYDROARTEMISININ ; MECHANISMS ; IMMUNITY ; CELLS
资助项目National Key R&D Program of China[2024YFC3506200] ; National Key R&D Program of China[2024YFC3506205] ; National Natural Science Foundation of China[82374108] ; National Natural Science Foundation of China[82322076] ; Shanghai Municipal Science and Technology Major Project ; State Key Laboratory of Drug Research Program[SIMM1903ZZ-03] ; CAS Interdisciplinary Innovation Team ; Shanghai Frontiers Science Center for TCM Chemical Biology ; Natural Science Research of Jiangsu Higher Education Institutions of China[1020241311]
WOS研究方向Chemistry ; Pharmacology & Pharmacy
语种英语
WOS记录号WOS:001680590500001
出版者NATURE PUBL GROUP
源URL[http://119.78.100.183/handle/2S10ELR8/322746]  
专题国家级研究中心_原创新药研究全国重点实验室
通讯作者He, Shi-jun; Xu, Han-chen; Lin, Ze-min
作者单位1.Fudan Univ, Shanghai Pudong Hosp, Human Phenome Inst, Pharmacophen Lab, Shanghai 201203, Peoples R China
2.Shanghai Univ Tradit Chinese Med, Longhua Hosp, Innovat Res Inst Tradit Chinese Med, Shanghai 201203, Peoples R China
3.Shanghai Univ Tradit Chinese Med, State Key Lab Integrat & Innovat Class Formula & M, Shanghai 200032, Peoples R China
4.Shanghai Univ Tradit Chinese Med, Longhua Hosp, Inst Digest Dis, China Canada Ctr Res Digest Dis ccCRDD, Shanghai 200032, Peoples R China
5.Chinese Acad Sci, Shanghai Inst Mat Med, Lab Immunopharmacol, State Key Lab Drug Res, Shanghai 201203, Peoples R China
6.Univ Chinese Acad Sci, Sch Pharm, Beijing 100049, Peoples R China
推荐引用方式
GB/T 7714		 He, Shi-jun,Tang, Mei-lin,Chen, Li,et al. Rebalancing the inflammatory trajectory from inflammatory bowel disease to colitis-associated colorectal cancer via artemisinin-based multitarget therapy[J]. ACTA PHARMACOLOGICA SINICA,2026:14.
APA He, Shi-jun,Tang, Mei-lin,Chen, Li,Zuo, Jian-ping,Xu, Han-chen,&Lin, Ze-min.(2026).Rebalancing the inflammatory trajectory from inflammatory bowel disease to colitis-associated colorectal cancer via artemisinin-based multitarget therapy.ACTA PHARMACOLOGICA SINICA,14.
MLA He, Shi-jun,et al."Rebalancing the inflammatory trajectory from inflammatory bowel disease to colitis-associated colorectal cancer via artemisinin-based multitarget therapy".ACTA PHARMACOLOGICA SINICA (2026):14.

入库方式： OAI收割

来源：上海药物研究所

浏览0
下载0
收藏0
其他版本

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。